REGiMMUNE
PrivateLast Round
Private Equity
Sep 22, 2025
Total Funding Raised
$46M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
REGiMMUNE operates in Healthcare & Life Sciences and is based in Taipei. Its latest recorded funding round was a Series E round in April 2017.
REGiMMUNE is a clinical-stage biopharmaceutical company that develops innovative immunotherapies by harnessing the power of regulatory T cells (Tregs) to treat immune disorders and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
REGiMMUNE Comparables
Compare REGiMMUNE with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Treg Therapeutics | 77% | |
| Swedish Orphan Biovitrum | 77% | |
| COUR Pharmaceuticals | 76% |
For institutional investors. Book with your work email.
REGiMMUNE Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Sep 22, 2025 | ||||
| Series E | Apr 7, 2017 | ||||
| Series D | Feb 14, 2014 | ||||
| Private Placement | Mar 28, 2012 | ||||
| Series C | Jan 31, 2012 | ||||
Grant | Dec 8, 2008 |
For institutional investors. Book with your work email.
REGiMMUNE Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| JAFCO Group Co., Ltd. | Series A |
| Shinkin Capital Co., Ltd. | Series C |
| Mizuho Capital | Series D |
| Yasuda Enterprise Development | Series A, Series B |
| Oita Venture Capital Co., Ltd. | Series E |
| Daiwa Corporate Investment Co., Ltd. | Series B |
| WHIZ Partners, Inc. | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 229% MoM, reaching 2.4K.
- May 14, 2026
Monthly visitors increased 51% MoM.
For institutional investors. Book with your work email.
REGiMMUNE Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about REGiMMUNE's valuation, stock price, and market status.
Is REGiMMUNE a public or private company?
REGiMMUNE is a private company.
What is the current stock price of REGiMMUNE?
REGiMMUNE is a private company, so its shares have no public market price. Caplight tracks REGiMMUNE's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is REGiMMUNE worth (valuation)?
Valuation information for REGiMMUNE is not publicly available.
Can I buy REGiMMUNE stock?
REGiMMUNE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was REGiMMUNE's last funding round?
REGiMMUNE's most recent funding round was Private Equity on September 22, 2025.
Who are the main investors in REGiMMUNE?
Key investors in REGiMMUNE include Japan Asia Investment Co., Ltd., SMBC Venture Capital.
Will REGiMMUNE IPO soon?
No public IPO plans have been announced for REGiMMUNE.
How can I track REGiMMUNE secondary market activity?
Caplight tracks bids, offers, and trades in REGiMMUNE's shares on secondary markets.